ears of C57BL/6J mice were treated topically with 5% cimetidine, a histamine type 2 receptor (H2r) antagonist, twice daily for 10 days. One hour after each cimetidine application, the right ear was treated topically with 10% histamine, while vehicle alone was applied to the left ear. Changes in melanin index were measured 24 h after the last application of histamine and vehicle as described in the human study. Results: In patients with vitiligo treated with vehicle alone for 5 weeks, the melanin index remained unchanged, while topical histamine treatment increased the melanin index by 38% ( p < 0.001 vs. both vehicle and pretreatment), which was paralleled by a >60% reduction in lesion surface area. Moreover, topical histamine accelerated permeability barrier recovery. No adverse events were observed following histamine applications. In mice, topical histamine significantly increased the melanin index, while topical co-applications of the H2r antagonist (cimetidine) prevented the expected histamineinduced increase in melanin index. Conclusions: These studies indicate that topical histamine or an H2r agonist could be useful for treating nonsegmental vitiligo, but further clinical studies in large populations will be required to validate the efficacy and safety of this approach.
The prevalence of vitiligo exceeds 8% in certain regions of the world [reviewed in 1 ] . Although the lesions are asymptomatic, vitiligo negatively impacts the quality of patients' lives [2, 3] . With regard to the etiology of vitiligo, there are several competing hypotheses, including autoimmune, gene mutations, oxidative stress, trauma, psychological stress, and/or combinations of these factors [4] [5] [6] [7] [8] [9] [10] [11] [12] . In part due to uncertainty about its etiology, optimal treatments are not yet available, although many approaches, including laser, high-potency topical steroids, topical immunomodulators, herbal medicines, as well as melanocyte/epidermal transplantation have yielded mixed results [13] [14] [15] [16] [17] [18] [19] [20] . Notably, the efficacy of most of these regimens is not only moderate, but also costly [21, 22] , and can provoke substantial side effects such as skin infections [23] [24] [25] [26] , skin atrophy, and/or disturbed epidermal permeability barrier homeostasis [27, 28] , which is already compromised in vitiligo [29] .
The pathological changes in the involved skin of vitiligo include loss of melanocytes, and reduced expression of histamine receptor 2 (H2r), but neither H1r nor H3r [30] [31] [32] . Because histamine stimulates melanogenesis and melanocyte proliferation in vitro [32] [33] [34] , we hypothesized that topical histamine could be efficacious in vitiligo. In the present study, we assessed the efficacy of topical histamine on skin pigmentation in normal pigmented mice and in patients with stable, nonsegmental vitiligo.
Materials and Methods

Human Study
Patients A total of 23 Chinese volunteers with stable, nonsegmental vitiligo vulgaris, including 14 males and 9 females aged 6-59 years, were enrolled in this study ( Table 1 ). The duration of vitiligo ranged from 0.2 to 6 years (2.39 ± 0.35). All subjects displayed at least 2 lesions, and all were of skin types III or IV (Fitzpatrick classification). None had been treated with topical or systemic medications for at least 2 weeks prior to enrollment and throughout the study period. The clinical diagnosis of vitiligo was verified by a dermatologist who is a vitiligo specialist, working in the Vitiligo Clinic of Dalian Skin Disease Hospital, PR China. Clinical examination showed no signs of inflammation in lesions. The study was approved by the Human Research Committee of Dalian Skin Disease Hospital, and it adhered to the ethical guidelines of the Declaration of Helsinki. All procedures performed in these studies involving human participants were performed in Dalian Skin Disease Hospital and were in accordance with the ethical standards of the institutional research committee, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual subjects prior to inclusion in this study.
Reagents and Treatment
Pure histamine was purchased from Macro-Union Pharmaceutical (Beijing, China). Because some patients have preference for the treated side, this study was not randomized. Six subjects wanted the lesion on the right side to serve as treated lesion while 17 patients had no preferences and a lesion on the left side served as treated site. One lesion on one side of each patient was covered with cotton gauze presoaked in 1% histamine in distilled water for 30 min twice daily for 5-11 weeks, while the adjacent or contralateral involved sites were covered with cotton gauze presoaked in distilled water alone, serving as control sites. All studies were carried out between the months of June and March.
Assessment of Efficacy
Melanin indices of histamine-and vehicle-treated sites, as well as contralateral, uninvolved normal skin sites were measured at baseline using a Mexameter ® MX 18 probe connected to a Multiprobe Adapter System (Courage-Khazaka, Cologne, Germany), and again after 5 weeks of treatments [29] . Melanin indices were expressed as percentage of normal skin, calculated according to the equation: (lesion melanin index/contralateral normal skin) × 100. For quantitative analysis of efficacy, lesions were also photographed before and after 5 weeks of treatments. Pictures of histamine-treated lesions were printed at the same magnification on glossy photo paper. Thirteen lesions, in which development of repigmentation began only on the edge, were cut out of the photos and weighed in a Mettler Toledo AG285 balance. Reduction in lesion size was calculated using the equation: (pretreatment weight -posttreatment weight)/pretreatment × 100. Transepidermal water loss rates, an indicator of epidermal permeability barrier function in lesions, were measured with a TM300 probe, connected to a Courage-Khazaka MPA5 prior to and after 5 weeks of treatments, as described previously [29] . After 5 weeks of treatments, the barrier recovery rate was assessed 3 h after acute barrier perturbation by sequential D-squame applications [29] .
Animal Study
Eight-to 10-week-old C57BL/6J mice were purchased from the Animal Center of National Cheng Kung University (Tainan, Taiwan). Both pure histamine and pure cimetidine were purchased from Sigma (St. Louis, MO, USA). Due to the movement of mice and skin surface tension, it is difficult to keep water solution on a mouse ear for long enough following topical application. There- 141 fore, ethanol was used as vehicle in the animal study. In one group of mice, both ears were treated topically with vehicle (30 μL of 90% ethanol) twice daily for 2 weeks. One hour after each vehicle application, 30 μL of 10% histamine in 90% ethanol was applied to one ear, while vehicle was applied to the contralateral ear. In another group of mice, both ears were treated with 30 μL of 5% cimetidine twice daily for 2 weeks. One hour after each cimetidine application, 30 μL of vehicle and 10% histamine, respectively, were applied to the opposite ears. Before these experiments and 24 h after the last topical histamine applications, melanin indices were measured, as described above. This study was approved by the animal research committee of National Cheng Kung University. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures involving animals were in accordance with the ethical standards of the institution or practice at National Cheng Kung University.
Statistics
Data are expressed as means ± SEM. GraphPad Prism 4 software was used for all statistical analyses. A paired 2-tailed Student t test was used to determine the significance of reductions in lesion size before and after treatment. A 1-way ANOVA test was used to determine the significances in melanin indices and barrier recovery rates among treatment groups.
Results
Topical Histamine Induces Repigmentation in Stable, Nonsegmental Vitiligo
Since previous studies showed that histamine stimulates melanogenesis in vitro, we first assessed whether topical histamine induces repigmentation in stable, nonsegmental vitiligo. Our results showed that topical histamine began to induce repigmentation in most subjects after 2 weeks of treatment, becoming increasingly evident in most treated lesions by 3 weeks (red arrows in Fig. 1 a  vs. b) . Still more dramatic reductions in lesion size were seen after 11 weeks of treatments (red arrows in Fig. 1 c  vs. d) . In contrast, vehicle treatments did not induce repigmentation (data not shown). Notably, repigmentation appeared to begin both from hair follicles (red arrows in Fig. 1 b) and from the edge of lesions (red arrows in Fig. 1 d) .
Because the melanin index can objectively assess the response of vitiligo to treatments [35] , we next the measured melanin index before and after 5 weeks of treatments. The melanin index of vitiligo-involved sites declined by 71% in comparison to the uninvolved sites ( Fig. 1 e; 29.14 ± 4.41% of normal skin; p < 0.001). After 5 weeks of histamine treatment, the melanin index increased by over 130% from the pretreatment (188.91 ± 12.99 vs. 56.22 ± 8.62, p < 0.001). In contrast, the melanin index on vehicle-treated sites remained unchanged (60.83 ± 11.13). The improvement of melanin index did not correlate with disease duration ( r 2 = 0.007063). We next quantified the extent of changes in lesion size by comparing the weights of cut-out lesions, printed on paper, before and after 5 weeks of treatments. Histamine significantly reduced lesion size as demonstrated by 64.6 ± 8.9% reductions in paper weight in comparison to pretreatment (posttreatment vs. pretreatment, p = 0.0395). Because there were no visible signs of improvement in pigmentation after vehicle treatment, we did not assess the changes in lesion size in vehicle-treated sites. Together, these results demonstrate that topical histamine increases the melanin index and reduces lesion size in nonsegmental vitiligo.
While mild erythema and pruritus occurred in 6 patients after initial twice daily applications of histamine, these patients considered this adverse event to be tolerable. After given histamine once -rather than twice -daily, their symptoms disappeared after 3 days. Fifteen patients were followed up for 8 months, with lesion recurrence in 1 patient.
Topical Histamine Accelerates Permeability Barrier Recovery in Stable, Nonsegmental Vitiligo
Our previous studies demonstrated that epidermal pigmentation benefits the epidermal permeability barrier [36, 37] . To determine whether the topical histamine-induced improvement in pigmentation is paralleled by an enhancement of permeability barrier homeostasis, both basal transepidermal water loss and barrier recovery kinetics were assessed following 5 weeks of treatment of vitiligo lesions with topical histamine. Although basal transepidermal water loss rates of histamine-treated and vehicle-treated sites were comparable (12.4 ± 1.0 vs. 12.1 ± 1.0), permeability barrier recovery significantly accelerated in histamine-treated lesions in parallel with repigmentation in comparison with either untreated or vehicle-treated lesional sites ( Fig. 2 ) . In contrast, barrier recovery was delayed in involved vitiligo sites ( p < 0.05, histamine-treated vs. vehicle-treated and untreated lesional sites), as we demonstrated previously [29] . These results indicate that topical histamine-induced repigmentation is paralleled by enhanced epidermal permeability barrier homeostasis.
Taken together, these results demonstrate that topical histamine induces epidermal repigmentation and reduces lesion size in nonsegmental vitiligo, while enhancing rather than disrupting epidermal permeability barrier function. 
Topical Histamine Increases Skin Melanin Index via H2r
Because prior studies have shown that histamine stimulated melanogenesis via H2r in vitro [30] [31] [32] , we next determined whether topical histamine increases the melanin index via H2r in vivo. We measured the melanin index in mouse ears cotreated with histamine and an H2r antagonist, cimetidine. As shown in Figure 3 , 2 weeks of treatment of ears with topical histamine caused a modest, but significant increase in the skin melanin index (5.1% over the vehicle treatment, p = 0.0086). In contrast, pretreatment of ears with cimetidine, an H2r antagonist, completely prevented the changes in melanin index induced by histamine, while cimetidine alone did not affect melanin indices. These results are consistent with previous in vitro findings that histamine stimulates melanogenesis via H2r [32] . 
Discussion
Previous studies have shown that histamine stimulates melanocyte proliferation and melanogenesis in vitro [24] [25] [26] [27] [28] [29] [30] [31] [32] . We now show here that topical histamine consistently induces repigmentation in stable, nonsegmental vitiligo in humans, in parallel with increased melanin indices in histamine-treated normal mouse skin. The improvement of pigmentation likely does not result from residual benefits of prior treatments because vehicle-treated sites showed no improvement. The underlying mechanisms by which histamine benefits vitiligo likely reflect stimulation of melanocyte proliferation and melanogenesis, because addition of histamine to melanocyte cultures also stimulates melanocyte proliferation and melanogenesis [32] [33] [34] . However, histamine can also stimulate keratinocytes to secrete granulocyte-macrophage colony-stimulating factor [38] , which has been shown to stimulate melanocyte proliferation and differentiation [39] . Thus, histamine appears to increase melanin production by both direct and indirect mechanisms.
Although ethanol can affect the skin such as causing irritation, leading to skin pigmentation, the fact that coapplications of the H2r antagonist (cimetidine) prevented the histamine-induced hyperpigmentation in mice strongly suggests that (a) topical histamine solution-induced pigmentation is unlikely due to an ethanol-induced nonspecific effect and (b) the induction of melanin production by histamine occurs via the H2r, consistent with prior in vitro studies [32] . These results suggest that H2r agonists and likely antagonists could be used to manipulate skin pigmentation in clinical settings.
Although prior studies showed that histamine impairs the epidermal permeability barrier in vitro [40] and the antihistamines improve permeability barrier homeostasis [41] , we did not find any differences in basal transepidermal water loss rates between histamine-and vehicletreated vitiligo sites. In contrast, topical histamine-induced pigmentation is accompanied by an acceleration of permeability barrier recovery, consistent with our prior findings that pigmentation benefits permeability barrier homeostasis [36, 37] . While the mechanisms by which topical histamine improves the permeability barrier in vitiligo are unknown, Gutowska-Owsiak et al. [42] reported that histamine upregulates the expression of cornified envelope proteins, such as small proline-rich proteins and protease inhibitors. Pertinently, inhibition of proteases accelerates permeability barrier recovery in vivo [43] . Moreover, histamine-induced pigmentation could also attenuate the negative impact of histamine on Topical histamine improves epidermal permeability barrier homeostasis. Barrier perturbation was achieved by repeated Dsquame applications. Transepidermal water loss rates were measured on untreated, vehicle-treated and histamine-treated sites immediately and 3 h after barrier disruption with a Tewameter TM300 probe connected to an MPA5 unit. Data were normalized to normal skin, setting the recovery rate on normal skin as 100%. One-way ANOVA with Tukey's multiple comparison test was used to determine significances ( p < 0.05 treated sites vs. both untreated and vehicle-treated lesional sites). 144 permeability barrier homeostasis. Accordingly, the present study clearly shows that topical histamine improves pigmentation and permeability barrier homeostasis in stable, nonsegmental vitiligo. It is worth noting that only 1 out of 15 patients in the present study relapsed during an 8-month follow-up period, while the 1-year relapse rate after treatment is over 30% in other studies [44] , mandating that maintenance therapy may be required to sustain the improvements of repigmentation [45] . Moreover, no serious adverse reactions were observed in the present study. Finally, while the efficacy of laser treatment correlates negatively with disease duration [46] , the efficacy of histamine in the improvement of skin pigmentation is not affected by disease duration, suggesting that topical histamine could be an alternative approach for those with longer-term vitiligo.
Conclusion
This study demonstrates that topical histamine benefits nonsegmental vitiligo with minimal side effects, possibly providing a new therapeutic regimen for nonsegmental vitiligo. However, a double-blind, randomized study in a large population is required before histamine is widely employed in such clinical settings.
